CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural k…
| Métrica | GDTC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | -1227.1% | -32.5% | -1194.6% |
| FCF Margin | -1336.5% | -12.6% | -1323.9% |
| ROE | -60.8% | -39.2% | -21.6% |
| ROA | -49.9% | -30.9% | -18.9% |
| Current Ratio | 5.17 | 2.73 | +2.44 |
| Debt / Equity | 0.06 | 0.28 | -0.22 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -49.8% | — |
| ✗Flujo de caja operativo positivo | −SGD 4M | −SGD 3M |
| ✗Rentabilidad sobre activos al alza | -49.8% | -25.0% |
| ✓Caja operativa/activos supera al ROA | -46.3% | ROA -49.8% |
| ✗Menos deuda a largo plazo | 4.6% | 3.9% |
| ✗Mejor liquidez (ratio corriente) | 5.17 | 9.89 |
| ✗Sin aumentar el nº de acciones | 12M | 12M |
| –Margen bruto al alza | — | — |
| ✓Rotación de activos al alza | 0.04 | 0.01 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -1336.5% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 880.2% |
CytoMed Therapeutics Ltd cotiza a 0.88 USD y tiene una capitalización bursátil de $11M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud